|Articles|March 8, 2017
Tufts CSDD Releases Results of New Impact Report
A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.
Advertisement
A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Upskilling Community Cancer Centers: A Training Pilot Hints at Promising Ways to Boost Oncology Clinical Research
2
ACT Brief: AI-Enabled COA Migration, Expanding Trial Footprints into Routine Care, and New FDA Approval in Myasthenia Gravis
3
Integrating Trials into Routine Care
4
Noteworthy Focus Points That Help Differentiate Anti-Obesity Drug Development Strategies in a Rapidly Evolving and Expanding R&D Landscape
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
